文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

锻炼游戏治疗痴呆和轻度认知障碍。

Exergaming for dementia and mild cognitive impairment.

机构信息

Department of Psychology, University of Bath, Bath, UK.

Centre for the Analysis of Motion, Entertainment Research and Applications, University of Bath, Bath, UK.

出版信息

Cochrane Database Syst Rev. 2024 Sep 25;9(9):CD013853. doi: 10.1002/14651858.CD013853.pub2.


DOI:10.1002/14651858.CD013853.pub2
PMID:39319863
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11423707/
Abstract

BACKGROUND: Dementia and mild cognitive impairment are significant contributors to disability and dependency in older adults. Current treatments for managing these conditions are limited. Exergaming, a novel technology-driven intervention combining physical exercise with cognitive tasks, is a potential therapeutic approach. OBJECTIVES: To assess the effects of exergaming interventions on physical and cognitive outcomes, and activities of daily living, in people with dementia and mild cognitive impairment. SEARCH METHODS: On 22 December 2023, we searched the Cochrane Dementia and Cognitive Improvement Group's register, MEDLINE (Ovid SP), Embase (Ovid SP), PsycINFO (Ovid SP), CINAHL (EBSCOhost), Web of Science Core Collection (Clarivate), LILACS (BIREME), ClinicalTrials.gov, and the WHO (World Health Organization) meta-register the International Clinical Trials Registry Portal. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that recruited individuals diagnosed with dementia or mild cognitive impairment (MCI). Exergaming interventions involved participants being engaged in physical activity of at least moderate intensity, and used immersive and non-immersive virtual reality (VR) technology and real-time interaction. We planned to classify comparators as inactive control group (e.g. no treatment, waiting list), active control group (e.g. standard treatment, non-specific active control), or alternative treatment (e.g. physical activity, computerised cognitive training). Outcomes were to be measured using validated instruments. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for inclusion, extracted data, assessed the risk of bias using the Cochrane risk of bias tool RoB 2, and assessed the certainty of the evidence using GRADE. We consulted a third author if required. Where possible, we pooled outcome data using a fixed-effect or random-effects model. We expressed treatment effects as standardised mean differences (SMDs) for continuous outcomes and as risk ratios (RRs) for dichotomous outcomes, along with 95% confidence intervals (CIs). When data could not be pooled, we presented a narrative synthesis. MAIN RESULTS: We included 11 studies published between 2014 and 2023. Six of these studies were pre-registered. Seven studies involved 308 participants with mild cognitive impairment, and five studies included 228 individuals with dementia. One of the studies presented data for both MCI and dementia separately. Most comparisons exhibited a high risk or some concerns of bias. We have only low or very low certainty about all the results presented below. Effects of exergaming interventions for people with dementia Compared to a control group Exergaming may improve global cognitive functioning at the end of treatment, but the evidence is very uncertain (SMD 1.47, 95% 1.04 to 1.90; 2 studies, 113 participants). The evidence is very uncertain about the effects of exergaming at the end of treatment on global physical functioning (SMD -0.20, 95% -0.57 to 0.17; 2 studies, 113 participants) or activities of daily living (ADL) (SMD -0.28, 95% -0.65 to 0.09; 2 studies, 113 participants). The evidence is very uncertain about adverse effects due to the small sample size and no events. Findings are based on two studies (113 participants), but data could not be pooled; both studies reported no adverse reactions linked to the intervention or control group. Compared to an alternative treatment group At the end of treatment, the evidence is very uncertain about the effects of exergaming on global physical functioning (SMD 0.14, 95% -0.30 to 0.58; 2 studies, 85 participants) or global cognitive functioning (SMD 0.11, 95% -0.33 to 0.55; 2 studies, 85 participants). For ADL, only one study was available (n = 67), which provided low-certainty evidence of little to no difference between exergaming and exercise. The evidence is very uncertain about adverse effects of exergaming compared with alternative treatment (RR 7.50, 95% CI 0.41 to 136.52; 2 studies, 2/85 participants). Effects of exergaming interventions for people with mild cognitive impairment (MCI) Compared to a control group Exergaming may improve global cognitive functioning at the end of treatment for people with MCI, but the evidence is very uncertain, (SMD 0.79, 95% 0.05 to 1.53; 2 studies, 34 participants). The evidence is very uncertain about the effects of exergaming at the end of treatment on global physical functioning (SMD 0.27, 95% -0.41 to 0.94; 2 studies, 34 participants) and ADL (SMD 0.51, 95% -0.01 to 1.03; 2 studies, 60 participants). The evidence is very uncertain about the effects of exergaming on adverse effects due to a small sample size and no events (0/14 participants). Findings are based on one study. Compared to an alternative treatment group The evidence is very uncertain about global physical functioning at the end of treatment. Only one study was included (n = 45). For global cognitive functioning, we included four studies (n = 235 participants), but due to considerable heterogeneity (I² = 96%), we could not pool results. The evidence is very uncertain about the effects of exergaming on global cognitive functioning. No study evaluated ADL outcomes. The evidence is very uncertain about adverse effects of exergaming due to the small sample size and no events (n = 123 participants). Findings are based on one study. AUTHORS' CONCLUSIONS: Overall, the evidence is very uncertain about the effects of exergaming on global physical and cognitive functioning, and ADL. There may be an improvement in global cognitive functioning at the end of treatment for both people with dementia and people with MCI, but the evidence is very uncertain. The potential benefit is observed only when exergaming is compared with a control intervention (e.g. usual care, listening to music, health education), and not when compared with an alternative treatment with a specific effect, such as physical activity (e.g. standing and sitting exercises or cycling). The evidence is very uncertain about the effects of exergaming on adverse effects. All sessions took place in a controlled and supervised environment. Therefore, we do not know if exergaming can be safely used in a home environment, unsupervised.

摘要

背景:痴呆症和轻度认知障碍是导致老年人残疾和依赖的重要因素。目前治疗这些疾病的方法有限。而作为一种新的技术驱动的干预手段,健智游戏将身体运动与认知任务相结合,可能是一种有前途的治疗方法。

目的:评估健智游戏干预对痴呆症和轻度认知障碍患者的身体和认知结果以及日常生活活动的影响。

检索方法:2023 年 12 月 22 日,我们检索了 Cochrane 痴呆症和认知改善组登记处、Cochrane 图书馆、MEDLINE(Ovid SP)、Embase(Ovid SP)、PsycINFO(Ovid SP)、CINAHL(EBSCOhost)、Web of Science 核心合集(Clarivate)、LILACS(BIREME)、ClinicalTrials.gov 和世界卫生组织(WHO)国际临床试验注册平台的临床试验注册数据库。

选择标准:我们纳入了招募被诊断为痴呆症或轻度认知障碍(MCI)患者的随机对照试验(RCTs)。健智游戏干预包括参与者进行至少中等强度的身体活动,并使用沉浸式和非沉浸式虚拟现实(VR)技术和实时交互。我们计划将对照分为无治疗组(例如,不治疗、等待名单)、阳性对照组(例如,标准治疗、非特异性阳性对照)或替代治疗组(例如,身体活动、计算机认知训练)。结果将使用经过验证的工具进行测量。

数据收集和分析:两名综述作者独立选择纳入的研究,提取数据,使用 Cochrane 偏倚风险工具 RoB 2 评估风险偏倚,并使用 GRADE 评估证据的确定性。如有需要,我们会咨询第三名作者。在可能的情况下,我们使用固定效应或随机效应模型对结果数据进行合并。我们以标准化均数差(SMD)表示连续性结局,以风险比(RR)表示二分类结局,并给出 95%置信区间(CI)。当无法合并数据时,我们进行了叙述性综合。

主要结果:我们纳入了 11 项发表于 2014 年至 2023 年之间的研究。其中 6 项研究为预注册。7 项研究纳入了 308 名轻度认知障碍患者,5 项研究纳入了 228 名痴呆症患者。其中一项研究分别报告了 MCI 和痴呆症的数据。大多数比较的偏倚风险较高或存在一些关注。我们对下面呈现的所有结果的确定性都只有低或非常低。

健智游戏对痴呆症患者的影响:与对照组相比,健智游戏可能会改善治疗结束时的整体认知功能,但证据非常不确定(SMD 1.47,95%置信区间 1.04 至 1.90;2 项研究,113 名参与者)。治疗结束时,健智游戏对整体身体功能(SMD -0.20,95%置信区间 -0.57 至 0.17;2 项研究,113 名参与者)或日常生活活动(ADL)(SMD -0.28,95%置信区间 -0.65 至 0.09;2 项研究,113 名参与者)的影响的证据也非常不确定。由于样本量小且无事件发生,对不良影响的证据非常不确定。该发现基于两项研究(113 名参与者),但数据无法合并;两项研究均报告无与干预或对照组相关的不良反应。

与替代治疗组相比,在治疗结束时,健智游戏对整体身体功能(SMD 0.14,95%置信区间 0.30 至 0.58;2 项研究,85 名参与者)或整体认知功能(SMD 0.11,95%置信区间 0.33 至 0.55;2 项研究,85 名参与者)的影响的证据非常不确定。对于 ADL,只有一项研究(n = 67)可用,提供了健智游戏与运动相比在 ADL 方面无差异或差异很小的低确定性证据。与替代治疗相比,健智游戏的不良影响的证据非常不确定(RR 7.50,95%置信区间 0.41 至 136.52;2 项研究,2/85 名参与者)。

健智游戏对轻度认知障碍(MCI)患者的影响:与对照组相比,健智游戏可能会改善 MCI 患者治疗结束时的整体认知功能,但证据非常不确定(SMD 0.79,95%置信区间 0.05 至 1.53;2 项研究,34 名参与者)。治疗结束时,健智游戏对整体身体功能(SMD 0.27,95%置信区间 0.41 至 0.94;2 项研究,34 名参与者)和 ADL(SMD 0.51,95%置信区间 0.01 至 1.03;2 项研究,60 名参与者)的影响的证据也非常不确定。由于样本量小且无事件发生,对健智游戏不良影响的证据非常不确定(0/14 名参与者)。该发现基于一项研究。

与替代治疗组相比,治疗结束时整体身体功能的证据非常不确定。只有一项研究(n = 45)纳入了该组。对于整体认知功能,我们纳入了四项研究(n = 235 名参与者),但由于存在很大的异质性(I² = 96%),我们无法合并结果。健智游戏对整体认知功能的影响的证据也非常不确定。没有研究评估 ADL 结局。由于样本量小且无事件发生,对健智游戏不良影响的证据非常不确定(n = 123 名参与者)。该发现基于一项研究。

作者结论:总体而言,健智游戏对痴呆症和 MCI 患者的整体身体和认知功能以及日常生活活动的影响的证据非常不确定。健智游戏可能会改善痴呆症和 MCI 患者治疗结束时的整体认知功能,但证据非常不确定。这种益处仅在健智游戏与对照干预(例如,常规护理、听音乐、健康教育)相比时观察到,而与具有特定效果的替代治疗(例如,站立和坐姿运动或骑自行车)相比时则没有观察到。健智游戏对不良影响的证据非常不确定。所有的治疗都在受控和监督的环境中进行。因此,我们不知道健智游戏是否可以在无人监督的家庭环境中安全使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/6d581b49b725/tCD013853-CMP-009.06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/ca52a98a9694/tCD013853-FIG-01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/ed64c232c762/tCD013853-CMP-001.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/10bf1b08c574/tCD013853-CMP-001.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/827795ae642b/tCD013853-CMP-001.03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/fba8a40017f3/tCD013853-CMP-002.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/35ef26a4868b/tCD013853-CMP-002.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/3c92a8e5d6fe/tCD013853-CMP-002.03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/78da64493814/tCD013853-CMP-002.04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/814f6674531c/tCD013853-CMP-003.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/d7752c1b8e7f/tCD013853-CMP-003.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/09d4550c1377/tCD013853-CMP-003.03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/db7c76c2ed97/tCD013853-CMP-003.04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/2aa6cf92d493/tCD013853-CMP-003.05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/a39f8370c2bf/tCD013853-CMP-003.06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/14aaa11e47f7/tCD013853-CMP-007.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/3d4725243bad/tCD013853-CMP-007.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/0a1d12013f44/tCD013853-CMP-008.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/8f905d8b7fd7/tCD013853-CMP-009.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/9cf83ad79976/tCD013853-CMP-009.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/84e756ee8613/tCD013853-CMP-009.03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/e838939acc6d/tCD013853-CMP-009.04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/16f5e28a63c8/tCD013853-CMP-009.05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/6d581b49b725/tCD013853-CMP-009.06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/ca52a98a9694/tCD013853-FIG-01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/ed64c232c762/tCD013853-CMP-001.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/10bf1b08c574/tCD013853-CMP-001.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/827795ae642b/tCD013853-CMP-001.03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/fba8a40017f3/tCD013853-CMP-002.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/35ef26a4868b/tCD013853-CMP-002.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/3c92a8e5d6fe/tCD013853-CMP-002.03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/78da64493814/tCD013853-CMP-002.04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/814f6674531c/tCD013853-CMP-003.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/d7752c1b8e7f/tCD013853-CMP-003.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/09d4550c1377/tCD013853-CMP-003.03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/db7c76c2ed97/tCD013853-CMP-003.04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/2aa6cf92d493/tCD013853-CMP-003.05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/a39f8370c2bf/tCD013853-CMP-003.06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/14aaa11e47f7/tCD013853-CMP-007.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/3d4725243bad/tCD013853-CMP-007.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/0a1d12013f44/tCD013853-CMP-008.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/8f905d8b7fd7/tCD013853-CMP-009.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/9cf83ad79976/tCD013853-CMP-009.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/84e756ee8613/tCD013853-CMP-009.03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/e838939acc6d/tCD013853-CMP-009.04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/16f5e28a63c8/tCD013853-CMP-009.05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396b/11423707/6d581b49b725/tCD013853-CMP-009.06.jpg

相似文献

[1]
Exergaming for dementia and mild cognitive impairment.

Cochrane Database Syst Rev. 2024-9-25

[2]
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Cochrane Database Syst Rev. 2022-2-1

[3]
Music-based therapeutic interventions for people with dementia.

Cochrane Database Syst Rev. 2025-3-7

[4]
Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease.

Cochrane Database Syst Rev. 2020-2-26

[5]
Multi-domain interventions for the prevention of dementia and cognitive decline.

Cochrane Database Syst Rev. 2021-11-8

[6]
Psychological treatments for depression and anxiety in dementia and mild cognitive impairment.

Cochrane Database Syst Rev. 2022-4-25

[7]
Computerised cognitive training for 12 or more weeks for maintaining cognitive function in cognitively healthy people in late life.

Cochrane Database Syst Rev. 2020-2-27

[8]
Cognitive training for people with mild to moderate dementia.

Cochrane Database Syst Rev. 2019-3-25

[9]
Dance movement therapy for dementia.

Cochrane Database Syst Rev. 2023-8-7

[10]
Exercise therapy for chronic fatigue syndrome.

Cochrane Database Syst Rev. 2024-12-19

引用本文的文献

[1]
Domain-Specific Evaluation of Exergame Metrics Among Older Adults With Mild Neurocognitive Disorder: Secondary Analysis of 2 Randomized Controlled Trials.

JMIR Serious Games. 2025-5-21

[2]
Associations between reversible and potentially reversible cognitive frailty and falls in community-dwelling older adults in China: a longitudinal study.

BMC Geriatr. 2025-4-5

[3]
Is exergaming a viable exercise option for obese black women?

Contemp Clin Trials. 2025-4

[4]
Immersive virtual reality or computerised mindfulness meditation for improving mood? Preliminary efficacy from a pilot randomised trial.

Front Psychol. 2023-10-25

本文引用的文献

[1]
Cognitive stimulation to improve cognitive functioning in people with dementia.

Cochrane Database Syst Rev. 2023-1-31

[2]
Feasibility, usability, and acceptance of "Brain-IT"-A newly developed exergame-based training concept for the secondary prevention of mild neurocognitive disorder: a pilot randomized controlled trial.

Front Aging Neurosci. 2023-9-21

[3]
Cognitive rehabilitation for people with mild to moderate dementia.

Cochrane Database Syst Rev. 2023-6-29

[4]
Effects of exergaming in older individuals with mild cognitive impairment and dementia: A systematic review and meta-analysis.

Geriatr Nurs. 2023

[5]
The Effects of Exergaming on Executive and Physical Functions in Older Adults With Dementia: Randomized Controlled Trial.

J Med Internet Res. 2023-3-7

[6]
The feasibility of a stepping exergame prototype for older adults with major neurocognitive disorder residing in a long-term care facility: a mixed methods pilot study.

Disabil Rehabil. 2023-2-23

[7]
Public attitudes towards the use of novel technologies in their future healthcare: a UK survey.

BMC Med Inform Decis Mak. 2023-2-22

[8]
Effectiveness of an Individualized Exergame-Based Motor-Cognitive Training Concept Targeted to Improve Cognitive Functioning in Older Adults With Mild Neurocognitive Disorder: Study Protocol for a Randomized Controlled Trial.

JMIR Res Protoc. 2023-2-6

[9]
SMARTfit Dual-Task Exercise Improves Cognition and Physical Function in Older Adults With Mild Cognitive Impairment: Results of a Community-Based Pilot Study.

J Aging Phys Act. 2023-8-1

[10]
Analysis of cluster randomised trials as if they were individually randomised.

Lancet Diabetes Endocrinol. 2023-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索